As of close of business last night, T2 Biosystems Inc.’s stock clocked out at $0.28, up 3.21% from its previous closing price of $0.27. In other words, the price has increased by $+0.0088 from its previous closing price. On the day, 770256 shares were traded. TTOO stock price reached its highest trading level at $0.2900 during the session, while it also had its lowest trading level at $0.2673.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
To gain a deeper understanding of TTOO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.90.
Upgrades & Downgrades
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 28 when Gibbs Michael Terrence sold 239 shares for $0.48 per share. The transaction valued at 115 led to the insider holds 6,612 shares of the business.
Sperzel John J III sold 2,898 shares of TTOO for $1,710 on Feb 28. The Chairman and CEO now owns 17,329 shares after completing the transaction at $0.59 per share. On Feb 28, another insider, Gibbs Michael Terrence, who serves as the General Counsel of the company, sold 1,585 shares for $0.59 each. As a result, the insider received 935 and left with 6,517 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TTOO now has a Market Capitalization of 8.52M and an Enterprise Value of 57.40M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26. Its current Enterprise Value per Revenue stands at 2.57 whereas that against EBITDA is -1.07.
Stock Price History:
Over the past 52 weeks, TTOO has reached a high of $15.00, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.3904, while the 200-Day Moving Average is calculated to be 2.2973.
It appears that TTOO traded 628.43K shares on average per day over the past three months and 639.94k shares per day over the past ten days. A total of 20.28M shares are outstanding, with a floating share count of 20.09M. Insiders hold about 0.30% of the company’s shares, while institutions hold 6.80% stake in the company. Shares short for TTOO as of Apr 27, 2023 were 501.47k with a Short Ratio of 0.50M, compared to 570.46k on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.47% and a Short% of Float of 2.49%.
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.2 for the current quarter, with a high estimate of -$1.1 and a low estimate of -$1.4, while EPS last year was -$5. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.33 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$1.56 and -$5.19 for the fiscal current year, implying an average EPS of -$2.93. EPS for the following year is -$2.09, with 3 analysts recommending between -$0.69 and -$4.65.
In the current quarter, 3 analysts expect revenue to total $2.33M. It ranges from a high estimate of $2.8M to a low estimate of $2.1M. As of the current estimate, T2 Biosystems Inc.’s year-ago sales were $7.23M, an estimated decrease of -67.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $2.57M, a decrease of -56.50% over than the figure of -$67.80% in the same quarter last year. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $2.4M.
A total of 3 analysts have provided revenue estimates for TTOO’s current fiscal year. The highest revenue estimate was $17.2M, while the lowest revenue estimate was $11.5M, resulting in an average revenue estimate of $13.73M. In the same quarter a year ago, actual revenue was $22.3M, down -38.40% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $25.53M in the next fiscal year. The high estimate is $31.8M and the low estimate is $17M. The average revenue growth estimate for next year is up 85.90% from the average revenue estimate for this year.